The Compound — News
The GLP-1 pill is here
The injectable model has been the single biggest barrier to GLP-1 adoption. Millions of people who would benefit from these drugs will not self-inject. Oral options are now real. Here is what actually changed.
Oral semaglutide already existed — this is different
Rybelsus, an oral semaglutide pill for type 2 diabetes, has been available since 2019. But it was a lower-dose formulation for blood sugar control, not weight loss, and came with strict fasting requirements that made it inconvenient. Most people in the GLP-1 weight loss conversation did not think of it as an option.
In January 2026, Novo Nordisk launched an oral version of Wegovy specifically for weight loss. Same active ingredient as the injection, different delivery system. Clinical data shows roughly 13–15% body weight loss versus 15–17% for the injectable — a real but modest gap.
The fasting requirement still applies. You take the pill on an empty stomach with 4 ounces of water and wait 30 minutes before eating or drinking anything else. The reason: oral semaglutide has very low bioavailability (roughly 1%) — the special formulation helps the drug survive stomach acid, but the fasting window is necessary to maximize absorption. Miss the window and you absorb less drug.
Orforglipron changes the equation
Eli Lilly's orforglipron is a different kind of drug. It is not a peptide — it is a small molecule that activates the GLP-1 receptor. That distinction is what makes oral administration simpler: small molecules survive the digestive system without special formulations, without fasting windows, without complex timing.
Phase 3 results were strong. Foundayo received FDA approval on April 1, 2026. It is a once-daily pill with no fasting requirement, closer to how you would take any other medication. For a side-by-side breakdown of both approved oral pills on weight loss, tolerability, and dosing requirements, see the oral semaglutide vs orforglipron comparison.
| Injectable Wegovy | Oral Wegovy | Orforglipron | |
|---|---|---|---|
| Weight loss | 15–17% | 13–15% | TBD (Phase 3 strong) |
| Dosing | Weekly injection | Daily pill | Daily pill |
| Fasting required | No | 30 min window | No |
| Cold storage | Yes | No | No |
| FDA status | Approved | Approved Jan 2026 | Expected Q2 2026 |
| Compounded option | Yes (varies) | No | No |
Who should consider the pill
If you are comfortable self-injecting, the injectable is modestly more effective and the compounded option makes it significantly cheaper. The pill does not improve on the injection in any clinical metric.
But effectiveness you will not take beats effectiveness you cannot maintain. If needle phobia, travel, cold storage logistics, or simple preference means you would not stick with an injectable, the oral option is the better real-world choice. A 14% weight loss you actually achieve is better than a 16% weight loss you abandon after two months.
What is coming next in oral GLP-1s
A third oral GLP-1 is moving through Phase 2 with numbers that are drawing attention. Aleniglipron, from Structure Therapeutics, is also a small-molecule GLP-1 agonist with no fasting window. In Phase 2, it produced 16.3% placebo-adjusted weight loss at 44 weeks, the highest figure among oral GLP-1 drugs at that stage. Phase 3 is planned to start in Q3 2026. For the full breakdown of what the trial data showed, see what is aleniglipron.
A fourth candidate, CX11 from Corxel Pharmaceuticals, reported Phase 2 topline results in June 2026: 11.5% weight loss at 36 weeks, also with no fasting window. It is earlier-stage than orforglipron or aleniglipron, with a global Phase 3 trial not targeted to start until early 2027. See what is CX11 for the full trial breakdown.
The cost picture
Novo Nordisk launched oral Wegovy at around $149/month without insurance, significantly cheaper than the injectable, which runs $1,300 or more without coverage. That pricing was a deliberate move to widen access. There is still no compounded oral option: the shortage resolution that enabled compounded injectable semaglutide does not apply to the pill formulation, and the oral patents are separate.
Orforglipron pricing has not been confirmed. The small-molecule format is cheaper to manufacture than a peptide, which may translate to lower list prices or better insurance coverage, but that is not settled yet.
